相关实验视频
Updated: Jan 10, 2026

08:17
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
Published on: October 30, 2016
21.9K
准RNA聚合酶I以促进自然杀手细胞在多发性骨髓瘤中的抗癌活性
Elena Sproviero1, Eleonora Gnocchini1, Tommaso Cipollone1
1Laboratory of Molecular Immunology and Immunopathology - Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Cell death & disease
|November 28, 2025
概括
新型RNA聚合酶I抑制剂通过调节自然杀手 (NK) 细胞活性和增强免疫疗法,在多发性髓瘤 (MM) 治疗中表现有前途,为抗药性癌症提供了新的策略.
科学领域:
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
- 药物发现 药物发现 药物发现
背景情况:
- 多发性骨髓瘤 (MM) 是一种无法治愈的血液癌症,由于药物耐药性,经常复发.
- 自然杀手 (NK) 细胞对抗MM免疫非常重要,但在瘤微环境中经常被抑制.
- 通过RNA聚合酶I (RNA Pol I) 转录向核糖体生物发生 (RiBi) 是MM的潜在治疗策略.
研究的目的:
- 研究两种RNA Pol I抑制剂CX-5461和BMH-21对多发性髓瘤 (MM) 的免疫调节作用.
- 了解RNA Pol I抑制如何影响MM的背景下NK细胞的识别和功能.
- 探索由RNA Pol I抑制驱动的新型免疫介导抗瘤机制.
主要方法:
- 用RNA Pol I抑制剂CX-5461和BMH-21治疗MM细胞.
- 评估NK细胞降粒,细胞因子分泌 (IFN-γ,TNF-α) 和配体表达.
- 对DNA损伤反应 (DDR),衰老和HLA-E表达的分析.
- 在HLA-E法规中调查信号通路 (ATR/AKT/mTORC1/S6K) 和先驱翻译轮 (PRT).
- 用daratumumab对抗体依赖细胞细胞毒性 (ADCC) 的评估.
主要成果:
- BMH-21表现出更强的免疫刺激作用,增强NK细胞降粒和细胞因子的产生.
- CX-5461诱导了DNA损伤反应 (DDR) 和衰老,导致HLA-E上调和抑制NK细胞活性.
- HLA-E表达通过ATR/AKT/mTORC1/S6K信号传递和PRT与DDR相关,PRT由莱纳利多米德和帕诺宾诺斯达调节.
- RNA Pol I 抑制显著增强了达拉图穆马布介导的对MM细胞的ADCC.
结论:
- RNA Pol I 抑制剂在多发性骨髓瘤中差异调节NK细胞介导的免疫力.
- 向RNA Pol I转录提供了一种双重方法:直接的抗癌效应和免疫系统增强.
- 这些发现揭示了新的免疫介导抗瘤机制和MM的潜在组合疗法.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cytotoxic T Cells-mediated Immune Response
6.4K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.4K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K

